Pharvaris announced that the Phase 3 RAPIDe-3 study results, published in The Lancet, demonstrate that oral deucrictibant provides rapid and sustained relief from hereditary angioedema (HAE) attacks, with symptom relief starting in about 1.3 hours and full resolution in under 12 hours. The drug was well tolerated and effective across various patient subgroups. Deucrictibant is under regulatory review by the FDA and EMA for on-demand HAE treatment, potentially becoming the first approved oral bradykinin B2 receptor antagonist. This advancement could offer a convenient oral option for patients who currently rely on injectable therapies.
The Phase 3 study results for deucrictibant in treating HAE attacks provide context for health sector activity on Pluang. Of 128 priced US health stocks, 51 rose and 76 fell. Notable movers include AbCellera Biologics Inc (ABCL) at USD 12.06, down 6.00%, CVS Health Corp (CVS) at USD 83.45, down 5.12%, and Immunovant Inc. (IMVT) at USD 30.43, down 5.02%. Data is as of Oct 09, 2026 03:21 WIB.
Tech analyst James Altucher highlights a publicly available but overlooked government filing that outlines Elon Musk's detailed plan for artificial intelligence. The filing, buried beneath the attention-grabbing SpaceX IPO news, reveals concrete step...
The Canine Project announced the launch of FURVIVE, an all-in-one restorative shampoo, conditioner, and body wash for dogs, set to release on October 15, 2026. Created by skincare experts, FURVIVE features Brazilian Copaiba and other premium skincare...
EnergyLIB is entering a new growth phase following a proposed strategic investment by Nasdaq-listed Cheche Group in its residential solar-plus-storage business, Long Way Fortune. This investment supports Cheche Group's expansion into the global resid...
Parex Resources announced its Q3 2026 average production reached 83,259 barrels of oil equivalent per day, driven by exploration success and a partnership with Ecopetrol. The company reaffirmed its H2 2026 production guidance of 82,000 to 91,000 boe/...
The Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased The Ensign Group securities between February 2022 and June 2026. The lawsuit alleges that Ensign systematically neglected elderly residents in its care facilitie...
